secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2025-09-24T23:59:59+00:00
Accession:  0001104659-25-092776
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences' Phase 3 ZYN002 trial in Fragile X syndrome fails primary endpoint
--------------------------------------------------------------------------------

- RECONNECT study did not meet primary endpoint of improvement in social avoidance; higher than expected placebo response cited.
- Study enrolled 215 patients aged 3 to <30 years; 1:1 randomization to ZYN002 or placebo over 18 weeks.
- CEO Jeffrey Dayno reaffirms late-stage pipeline; Phase 3 trials for pitolisant HD in narcolepsy and idiopathic hypersomnia on track for Q4 2025.
- Company describes itself as profitable and self-funding biotech with strong cash generation.
- Fragile X syndrome has no FDA-approved therapies; company will conduct comprehensive data analysis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000110465925092776/0001104659-25-092776-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000110465925092776/hrmy-20250924x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-092776

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer